Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.

Toni K Choueiri,Camillo Porta,Cristina Suárez,John Hainsworth, Eric Voog,Ignacio Duran,James Reeves,Piotr Czaykowski,Daniel Castellano,Jingjing Chen,Farhad Sedarati,Thomas Powles

The oncologist（2022）

引用 3|浏览7

暂无评分

摘要

Sapanisertib with or without TAK-117 was less tolerable and did not improve efficacy vs. everolimus in patients with advanced ccRCC who had relapsed after or were refractory to VEGF-targeted therapies. Dual mTORC1/2 inhibition may not be an effective therapeutic approach for these patients.

查看译文

关键词

MTOR inhibitors,clinical trial,everolimus,phase II,renal cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要